Variant Summary
- Also known as
- GLU545LYS,RS104886003
- HGVS
- NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A
- Variant Type(s)
- missense_variant
- Evidence Items
- 25
Evidence Level Distribution
Level B: 1Level C: 5Level D: 19
Evidence Items
Showing CIViC evidence rows where gene = PIK3CA and variant = E545K.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| D | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Pictilisib | 4 |
| D | Predictive | Does Not Support | Resistance | Her2-receptor Positive Breast Cancer | Trastuzumab Emtansine | 3 |
| C | Predictive | Does Not Support | Resistance | Colorectal Cancer | Cetuximab | 3 |
| D | Predictive | Supports | Sensitivity/Response | Cervix Carcinoma | Cisplatin,Pictilisib | 3 |
| D | Predictive | Supports | Resistance | Cervical Cancer | Cisplatin | 3 |
| C | Predictive | Supports | Resistance | Colorectal Cancer | Panitumumab,Cetuximab | 3 |
| D | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Lapatinib | 3 |
| D | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Trastuzumab | 3 |
| D | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Lapatinib,Trastuzumab | 3 |
| D | Predictive | Does Not Support | Resistance | Her2-receptor Positive Breast Cancer | Dactolisib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Akt Inhibitor MK2206,Pictilisib | 3 |
| D | Predictive | Supports | Resistance | Cervical Cancer | Cisplatin,Ionizing Radiotherapy | 3 |
| D | Predictive | Supports | Resistance | Lung Adenocarcinoma | Gefitinib | 2 |
| D | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Trastuzumab | 2 |
| C | Predictive | Supports | Resistance | Lung Adenocarcinoma | Erlotinib,Gefitinib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Pictilisib | 2 |
| C | Predictive | Does Not Support | Resistance | Colorectal Cancer | Panitumumab,Cetuximab | 2 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | PI103 | 2 |
| B | Prognostic | Supports | Poor Outcome | Rectum Cancer | 2 | |
| D | Predictive | Supports | Resistance | Melanoma | Vemurafenib | 2 |
| D | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Trastuzumab | 2 |
| C | Predictive | Supports | Sensitivity/Response | Cancer | Apitolisib | 1 |
| D | Predictive | Supports | Resistance | Breast Cancer | PI-103 | 1 |
| D | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | PI3Ka/Di | 1 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | PI3Ka/Di | 1 |